




#### Opioid Addiction: Addressing the Epidemic

William J. Lorman, JD, PhD, MSN, PMHNP-BC, FIAAN
Assistant Clinical Professor, Drexel University, Philadelphia, PA
V.P. & Chief Clinical Officer, Livengrin Foundation, Bensalem, PA
Adjunct Professor, Immaculata University, Dept. of Graduate Psychology
wjl27@drexel.edu

#### **NEUROBIOLOGY OF ADDICTION**

## Addiction and the Brain



## Addiction: The 5 C's

- 1) Continued use despite adverse consequences
- 2) Chronic
- 3) Control, loss of
- 4) Compulsive
- 5) Craving

### **Facts About Addiction**

- Addiction affects 25 million Americans
- 75% of addicts are in the workforce
- Only 9% of Americans who need treatment receive it
- New medications can help control craving
- Relapse is a normal part of the disease
- Treatment can work



# TRANSITION TO ADDICTION

Taking drugs may begin as a voluntary choice to seek a pleasant stimulus, but for addicts, that choice is no longer volitional, even in the face of terrible personal

## **Opioids**

• If dependence develops, drug procurement often dominates the individual's life and often leads to criminal behavior.

#### Heroin



•Heroin use is on the rise!

•Has a "city drug" stigma, however many suburban departments are seeing huge increases of the drug in higher socioeconomic areas

Pennsylvania has the highest heroin/opiate overdose death rate in the nation.

•Highly pure drug available

#### Heroin Overdose

## •Symptoms

- Airways and lungs
- ApneicShallow breathing
- Slow and labored breathing
  •Eyes, ears, nose, and throat
- Eyes, eur a, ...
  throat

   Dry mouth
   Extremely small pupils,
  sometimes as small as
  the head of a pin
  ('pinpoint pupils')
   Tongue discoloration

  \*Cardiac
   Hypotension
   Weak pulse
   Bradycardia

- Cyanosis Notable track marks/difficulty establishing an IV

- establishing an IV

  Stomach and intestines

  Constipation

  Spasms of the stomach and intestinal tract

  Nervous system

- -Coma
  -Delirium
  -Disorientation
  -Drowsiness
  -Muscle spasticity


### Withdrawal


- Symptoms start within 2 to 6 hours of last
- Abrupt withdrawal of short-acting opiates causes prompt and severe withdrawal symptoms


## Withdrawal Symptoms


- Rhinorrhea
- Yawning
- Loss of appetite
- Irritability


- Lacrimation
- Tremors
- Cramps
- Nausea
- Chills
- · Diaphoresis
- Body aches
- Panic














#### **High Risk Populations**


- □ People taking high daily doses of opioids
- □ People who "doctor shop"
- □ People using multiple abuseable substances like opioids, benzodiazepines, other CNS depressants, illicit drugs
- □ Low-income people and those living in rural areas
- Medicaid populations
- □ People with substance abuse or other mental health issues

Birnbaum H.G., Schiller M., Tang J., Katz N.P., Anaryts. Innoves. or an experience of a plant and a pl


### Other Risk Factors


- Past cocaine use, h/o alcohol or cannabis use1
- Lifetime history of substance use disorder<sup>2</sup>
- Family history of substance abuse, a history of legal problems and drug and alcohol abuse<sup>3</sup>
- Heavy tobacco use<sup>4</sup>
- History of severe depression or anxiety<sup>4</sup>
- Many patients with opiate addiction (up to 25% in some surveys), report that their addiction resulted from prescribed opioid analgesics.

 $^1$  Ives T et al. BMC Health Services Research 2006  $^{-2}$  Reid MC et al JGIM 2002  $^3$  Michna E el al. JPSM 2004  $^{-4}$  Akbik H et al. JPSM 2006









## Conversion Chart Equivalent of Morphine 10mg IV

Codeine - 120 mg\* Fentanyl - 0.1 mg Sufentanil - 0.014 mg Hydromorphone - 1.5 mg Levorphanol - 2 mg Meperidine - 75 mg Methadone - 10 mg

Heroin - 6 mg† (a bag of heroin is about 100mg) Oxycodone - 20 mg

Oxycodone - 20 mg Oxymorphone - 1 mg Buprenorphine - 0.3 mg

\* only IM/SC route; IV codeine is lethal

† this is a pharmaceutical grade heroin dose (morphine diacetate or also known as diacetyl-morphine); street heroin varies in potency and purity, so use with caution.

## PAIN & ITS MANAGEMENT IN ADDICTIVE POPULATIONS

## **Medical Perspectives**

- Persons with addictive disorders often do not receive regular health care.
  - Medical care for acute and chronic conditions can be fragmented and inefficient
  - They miss opportunities to receive preventive health care
  - In addition to the direct effects of intoxication, overdose and withdrawal, abused substances can affect every body system

#### Pain Treatment: The 4 A's of Assessment

- 1) Analgesic?
- 2) Adverse Effects?
- 3) Activities of Daily Life?
- 4) Aberrant Behaviors?/Predictors of Opioid Misuse

## Care During Hospitalization

- Three areas of attention:
  - Management of the drug withdrawal
  - Pain management
  - Common comorbidities

## Management of Withdrawal

- When a history of drug/alcohol dependence and recent use is obtained, withdrawal should be anticipated.
  - Persons not yet symptomatic with withdrawal but with past alcohol-related seizures or concomitant acute medical conditions (which increase the risk of withdrawal) should be treated with a benzodiazepine.
  - Because symptoms of withdrawal may not be distinguishable from systemic symptoms of infection, heart disease or neurologic conditions, treatment for withdrawal should proceed while investigations to identify other disorders continues.

#### Management of Overdose

#### Narcan (naloxone)

- Opioid antagonist
- •Counters the effects of opiate overdoses:
- -Heroin
- -Morphine
- -Vicodin
- -Codeine
- -Oxycodone
- -Fentanyl
- -Methadone

### Narcan (naloxone)

- May be administered intranasally (ALS or BLS)
- IV & IM are all ALS administration routes for Narcan
- Given in 2mg increments every five minutes, up to 6mg Opioid withdrawal syndrome may occur in some patients given large doses of Narcan.
- Severe side effects of Narcan:
- Emesis and aspiration, agitation, hypo- and hypertension, cardiac arrhythmias, dyspnea, pulmonary edema, encephalopathy, seizures, coma, and death. Narcan reduces constipation, and in repeat doses can cause explosive diarrhea.

## Management of Pain

- Pain management often becomes an issue.
  - Fear of causing or worsening addiction
    - This management style generally results in inadequate pain management and frustration for patient and provider.
  - With opiate dependence, pain control can be achieved only with substantially higher doses of opiates
    - Once a dose is determined, pain meds should be given on a regular schedule rather than as needed.

## **Types of Pain**

- Objective
  - Biological
  - Nociception
  - Pain
- Subjective
  - Psychological
  - Suffering
- "Pain is mandatory, suffering is optional."

## **Biological Pain Signals**

- Aching
- Sore
- Burning
- Sharp
- Tingling
- Cramping
- Pounding

## **Psychological Pain Signals**

- Awful
- Agonizing
- Torturing
- Dreadful
- Distressing
- Excruciating
- Grueling

## SIGNS OF ADDICTION IN PAIN PATIENTS:

#### "ABERRANT BEHAVIORS"

- · Lost or stolen Rx
- Escalating doses, early renewals
- Obtaining medication form other sources
- Use of pain medications for psychic effects, e.g. to relieve anxiety, increase energy, or for euphoria
- Unwillingness to try non-opioid mediations
- Deterioration in function

#### **PSEUDOADDICTION**

Behaviors that resemble addiction that occur when pain is under-treated.

- "Watching the clock" for pain medications in hospital
- "Drug seeking" and "doctor shopping"
- Asking for specific medications by name
- Hoarding of medications
- Unsanctioned escalation in dose

These behaviors resolve when the pain is adequately treated.

Aberrant Medication-Taking Behavior <u>More Likely</u> to be Suggestive of Addiction Red Flags

- Deterioration in functioning at work or socially
- Illegal activities selling, forging, buying from nonmedical sources
- Injection or snorting medication
- Multiple episodes of "lost" or "stolen" scripts
- Resistance to change therapy despite adverse effects
- Refusal to comply with random drug screens
- Concurrent abuse of alcohol or illicit drugs
- Use of multiple physicians and pharmacies

Aberrant Medication-Taking Behavior Less Likely to be Suggestive of Addiction Yellow Flags

- Complaints about need for more medication
- Drug hoarding
- Requesting specific pain medications
- Openly acquiring similar medications from other providers
- Occasional unsanctioned dose escalation
- Nonadherence to other recommendations for pain therapy



#### □ Focus areas

- I. Education
- II. Monitoring
- III. Disposal
- IV. Enforcement



- Enhance surveillance
- □ Inform policy
- □ Improve clinical practice







#### **Intervention Points**

- □ Pill mills
- Insurer and pharmacy benefit managers
- □ Problem prescribing
- General patients & the public
- General prescribing

□ EDs and hospitals

- People at high risk of overdose
- □ Pharmacies

- Intervention Recommendations
- Prescription drug monitoring programs
- Patient review and restriction programs
- □ Laws/regulations/policies
- Insurers and pharmacy benefit managers mechanisms
- Clinical guidelines



#### **Prescription Drug Monitoring Programs (PDMPs)**

- Operational in 42 states
- □ Focus PDMPs on
  - Patients at highest risk of abuse and overdose
  - Prescribers who clearly deviate from accepted medical practice
- Implement PDMP best practices



## Patient Review and Restriction Programs (aka "Lock-In" Programs)

- Applies to patients with inappropriate use of controlled substances
- 1 prescriber and 1 pharmacy for controlled substances
- Improve coordination of care and ensure appropriate access for patients at high risk for overdose
- Evaluations show cost savings as well as reductions in ED visits and numbers of providers and pharmacies



#### Laws/Regulations/Policies

- Some states have enacted laws and policies aimed at reducing diversion, abuse, and overdose
- Policies can strengthen health care provider accountability
- Safeguard access to treatment when implementing policies
- Rigorous evaluations to determine effectiveness and identify model aspects





## Insurer/Pharmacy Benefit Manager (PBM) Mechanisms

- Reimbursement incentives/disincentives
- □ Formulary development
- Quantity limits
- $\hfill \square$  Step therapies/prior authorization
- □ Real-time claims analysis
- □ Retrospective claims review programs









The findings and conclusions in this presentation are those of the author and do not necessarily represent the views of the Centers for Disease Control and Prevention.

## Thank you

### **Questions & Comments**





